. Small molecule WIN site inhibitors engage WDR5 in sensitive and non-sensitive cell lines. Related to Table 1. (A) Western blots of WDR5 reaction products from a representative CETSA assay. "Cmpd" refers to the concentration of each compound used, with the triangles indicating compound titrations. In each case, the top concentration used was 100 µM. Because of differing potencies, the dilution series were different for C3/C3nc (serial three-fold dilutions) versus C6/C6nc (serial five-fold dilutions). For each pair of active/inactive compounds, concentrations in MV4:11 and K562 cells were identical. Compound treatment was for one hour at 37 o C. (B) Quantification of CETSA data for C3 or C3nc in MV4:11 (left) and K562 (right) cells. Stabilization is defined as the percentage of soluble WDR5 at each dose point, relative to the total pool of non-denatured WDR5 protein. EC50 values for C3 in each cell type are shown above the graph. We could not obtain measurable EC50 values for C3nc in either cell type. Error bars represent SEM. (C) As in (B) but for C6 and C6nc. EC50 values for C6 in each cell type are shown above the graph. We could not obtain measurable EC50 values for C6nc in either cell type. Error bars represent SEM. (A) MV4:11 cells were treated with DMSO, or 2 µM C6 or C6nc, and samples collected at the indicated time points. Total cells, as well as live cells (trypan blue exclusion) were quantified and expressed as percentage viable cells. To prevent culture overgrowth, the DMSO-and C6nc-treated samples were replated at day three to the original starting density and treatment continued. Data from these same experiments is graphed as live cells/ml in Figure 2A . Error bars represent SEM. (B) Summary of flow cytometry analysis, examining the cell cycle distribution profile for MV4:11 cells treated with DMSO, or 2 µM C6 or C6nc, for the indicated times. The percentage of cells in each category for each timepoint is shown. These data were used to generate the stacked bar chart in Figure 2B . Error bars represent SEM. (C) Western blot, showing p53 levels in clones of MV4:11 cells CRISPR-targeted with either an EGFP (clones 4e and 5e) or a p53 (clones 1p and 8p) gRNA. Cells were treated with C6 or C6nc at 2 µM for 24 hours prior to analysis. (D) Dose-response curves for compound C6 (three day treatment) in the modified MV4:11 cells described in (C). The GI50 values are 4 µM for clone 4e, 5 µM for clone 5e, 18 µm for clone 1p, and 15 µM for clone 8p. Error bars represent SEM. analysis of FLAG (FL)-tagged WT WDR5, or WDR5 point mutants. FLAG-tagged proteins were recovered from HEK293 cells stably expressing the indicated WDR5 mutants, and probed for WDR5 or co-precipitating RBBP5. The F133A WDR5 mutant disrupts the WIN site, but retains RBBP5 binding. The L240K mutant disrupts the RBBP5 binding site. It, and the F133A/L240K WDR5 mutant, was included as a control for the specificity of the coIP; these mutants were not used further in this study. 
0.106 ± 0.013 19.9 ± 9.6 9,700 >20,000 5,100 >20,000 >20,000 C6nc -> 5,000 > 33.0 > 3000 -----Related to Figure 1 . K i was measured by competition assays, using either (i) fluorescence polarization anisotropy (FPA) with one of two different fluorescent WIN containing peptides (FITC-MLL and 10mer-Thr-FAM), or (ii) TR-FRET with the 10mer-Thr-FAM probe. Note that all FPA & TR-FRET data are n = 4; all HMT data is n = 2 except for compound 3 with MLL1 (n=18) and compound 6 with MLL1 (n=6). MLL1, MLL2, MLL3, and MLL4 HMT assays used an H3 peptide as substrate; SETD1A and SETD1B assays used core histones as substrate. "-" = not measured. 46.59, 53,25, 65.52 81.909, 86.973, 41.985 46.89, 54.22, 64,52 α, β, γ (°) 71. 94, 89.94, 73.61 90.00, 90.00, 90.00 70.19, 88.80, 74.41 Resolution (Å) 50.00-1.10 (1.12- 
